• Explore /
  • Poster
  • / Correlation of response with overall survival (OS) for nivolumab vs everolimus in advanced renal cell carcinoma (aRCC): Results from the phase III CheckMate 025 study.

Correlation of response with overall survival (OS) for nivolumab vs everolimus in advanced renal cell carcinoma (aRCC): Results from the phase III CheckMate 025 study.

Abstract Poster

Authors

null

Robert J. Motzer

Memorial Sloan Kettering Cancer Center, New York, NY

Robert J. Motzer , Padmanee Sharma , Bernard J. Escudier , David F. McDermott , Saby George , Sandy Srinivas , Scott S. Tykodi , Jeffrey Alan Sosman , Elizabeth R. Plimack , Paul D. Nathan , Viktor Gruenwald , Yoshihiko Tomita , Huanyu Zhao , Ian M. Waxman , Hans J. Hammers

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Nonprostate) Cancer

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT01668784

Citation

J Clin Oncol 34, 2016 (suppl; abstr 4552)

DOI

10.1200/JCO.2016.34.15_suppl.4552

Abstract #

4552

Poster Bd #

174

Abstract Disclosures

Similar Posters

First Author: Robert J. Motzer

First Author: Ruchit Shah

First Author: Bernard J. Escudier

First Author: Saby George